Value of Serum Neuron-Specific Enolase in Nonsmall Cell Lung Cancer

Díez, Mercedes Díaz de Cerio; Torres, Aracelis Z.; Ortega, Luís; Maestro, M.L.; Hernando, F.J. Serrano; Gomez, Ana Goas; Picardo, Antonio L.; Granell, Javier; Balibrea, J.L.

doi:10.1159/000227163

Cited by 29 publications

(19 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although NSE seems not to be closely related with the TNM stage [17], in our study high NSE levels were related to poor survival, in agreement with other reports [18]. Furthermore, in our study, NSE discriminated the large-cell NSCLC from SQCLC and adenocarcinoma, and it has been reported previously that patients with large-cell NSCLC had poor survival comparing with other NSCLC subtypes [19], as it was also noted in our study.…”

Section: Discussionsupporting

confidence: 91%

Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer

Hatzakis¹,

Froudarakis²,

Bouros³

et al. 2002

Respiration

View full text Add to dashboard Cite

Background: The role of tumor markers in the diagnosis and prognosis of lung cancer is under investigation. Objectives: The aim of this study was to investigate the diagnostic and prognostic significance of pre-therapeutic levels of various serum tumor markers, CYFRA 21-1, neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), CA 125 and squamous cell carcinoma antigen (SCCAg), in patients with lung cancer. Methods: We studied 102 consecutive patients (mean age 65.2 ± 11 years) with newly diagnosed lung cancer (96 males, 94%, with a mean age of 66.3 ± 10.5 years). All patients had a 5-year follow-up. Measurements of the serum tumor markers were performed on initial diagnosis. Results: Eighty-four patients (82%) had non-small-cell lung cancer (NSCLC) and 18 (18%) small-cell lung cancer (SCLC). From the 84 patients with NSCLC, 34 patients (33%) had squamous-cell lung cancer, 23 (22%) adenocarcinoma and 23 (22%) large-cell carcinomas. The overall median survival was 8.5 months. All SCLC patients had extensive disease with a median survival of 10.1 months and NSCLC patients of 8.4 months. Significant differences in the mean values of NSE and CYFRA 21-1 were observed between SCLC and NSCLC. In NSCLC, CYFRA 21-1, TPA, CA 125 and SCCAg serum levels were related to the stage of the disease at diagnosis, and CYFRA 21-1, NSE, TPA and CA-125 were related to a poor outcome. None of the above tumor markers was related to survival in the SCLC group. Conclusion: CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. Also, CYFRA 21-1 with TPA and CA 125 may provide useful information regarding the staging of the disease at diagnosis and the prognosis of patients with NSCLC.

show abstract

Section: Discussionsupporting

confidence: 91%

Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer

Hatzakis¹,

Froudarakis²,

Bouros³

et al. 2002

Respiration

View full text Add to dashboard Cite

show abstract

“…By contrast, in patients with NSCLC, the plasma NSE level has been shown to be associated with the patient survival rate. This association was observed in patients with NSCLC, regardless of whether they were treated by surgical resection, radiation therapy or chemotherapy (7)(8)(9)(10)(11). Furthermore, recently it has been reported that a higher pretreatment NSE level was associated with a shorter survival duration following the initiation of gefitinib in non-selective patients with NSCLC (13).…”

Section: Discussionmentioning

confidence: 97%

“…Furthermore, elevation of the pretreatment plasma NSE level has also been associated with poor outcomes in patients with NSCLC (7)(8)(9)(10)(11). We hypothesized that the blood level of pro-GRP and/or NSE may be associated with the clinical course following initiation of gefitinib therapy in patients with NSCLC harboring EGFR gene mutations.…”

Section: Introductionmentioning

confidence: 99%

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib

Inomata

Hayashi

Yamamoto

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Determination of the presence of epidermal growth factor receptor (EGFR) gene mutation is useful for predicting the efficacy of gefitinib. However, the survival rate following the initiation of treatment with gefitinib varies among individuals. A retrospective study was conducted to investigate the associations of the pretreatment serum pro-gastrin-releasing peptide (pro-GRP) and plasma neuron-specific enolase (NSE) levels to the patient survival rate following initiation of treatment with gefitinib in non-small cell lung cancer (NSCLC) patients receiving gefitinib treatment. Patients with NSCLC harboring EGFR gene mutations who received gefitinib therapy between 2004 and 2012 were included in the study. Data from a total of 41 patients were analyzed. The serum pro-GRP level was measured in 31 patients and the plasma NSE in 22 patients. The progression-free survival (PFS) (P=0.013) and overall survival (OS) (P=0.014, log-rank test) rates decreased as the plasma NSE level increased. Statistical analysis using a Cox proportional hazards regression model adjusted for age, gender, performance status (PS) and disease stage showed that higher NSE levels were associated with shorter PFS (P=0.021) and OS (P=0.0024). By contrast, no association was detected between the serum level of pro-GRP and survival rate. The results suggest that pretreatment NSE measurement could be clinically useful in patients with NSCLC scheduled to receive gefitinib treatment. IntroductionEpidermal growth factor receptor (EGFR) gene mutation is an important predictor of the response to EGFR-tyrosine kinase inhibitor (EGFR-TKI) treatment. Gefitinib treatment yields a longer progression-free survival (PFS) rate than cytotoxic drug therapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR gene mutations, including exon 19 deletion and exon 21 L858R (1-3). However, an important clinical problem is that in the majority of cases, the tumor cells soon acquire resistance to gefitinib.Several mechanisms of acquired resistance to gefitinib have been proposed. Hepatocyte growth factor has been shown to induce resistance to gefitinib of lung adenocarcinomas harboring EGFR gene mutations (4). An investigation of 37 cases with acquired resistance to gefitinib revealed the presence of the EGFR T790 mutation, MET amplification, transition from NSCLC to small cell lung cancer (SCLC), or PIK3CA mutation in these cases (5).Blood levels of pro-gastrin releasing peptide (pro-GRP) and neuron-specific enolase (NSE) have been reported to be frequently elevated in patients with SCLC (6), and their measurement has been utilized for diagnosis or evaluation of the treatment outcomes in these patients. Furthermore, elevation of the pretreatment plasma NSE level has also been associated with poor outcomes in patients with NSCLC (7-11). We hypothesized that the blood level of pro-GRP and/or NSE may be associated with the clinical course following initiation of gefitinib therapy in patients with NSCLC harboring EGFR gene mutations. To endorse its va...

show abstract

“…The increased number of errors in SCLC-LD patients is not surprising, as it is known that NSE is stage dependent in this type of cancer (Camey et al, 1982;Cooper 1994). An association between NSCLC and high NSE levels has been reported in a subgroup of patients (up to 30%), namely those showing an enhanced drug sensitivity and a more aggressive clinical tumour behaviour (Zandwjik et al, 1992;Diez et al, 1993).…”

Section: Discussionmentioning

confidence: 99%

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors

Paone

Angelis²,

Portalone³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary By means of a mathematical score previoulsy generated by discriminant analysis on 90 lung cancer patients, a new and larger group of 261 subjects [209 with non-small-cell lung cancer (NSCLC) and 52 with small-cell lung cancer (SCLC)] was analysed to confirm the ability of the method to distinguish between these two types of cancers. The score, which included the serum neuron-specific enolase (NSE) and CYFRA-21.1 levels, permitted correct classification of 93% of the patients. When the misclassifications were analysed in detail, the most frequent errors were associated with limited disease SCLC with low NSE levels and with advanced NSCLC with high NSE levels. This demonstrates the importance of the marker in correctly categorizing patients.

show abstract

Value of Serum Neuron-Specific Enolase in Nonsmall Cell Lung Cancer

Cited by 29 publications

References 9 publications

Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer

Prognostic Value of Serum Tumor Markers in Patients with Lung Cancer

Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib

Validation of an algorithm able to differentiate small-cell lung cancer (SCLC) from non-small-cell lung cancer (NSCLC) patients by means of a tumour marker panel: analysis of the errors

Contact Info

Product

Resources

About